Overview

• Dopamine boosts neprilysin, an enzyme that degrades beta-amyloid plaques linked to Alzheimer's.
• L-DOPA treatment in mice led to reduced plaques and improved memory function.
• Neprilysin levels naturally decrease with age, potentially serving as an early Alzheimer's biomarker.
• Further research needed to understand dopamine's regulation of neprilysin and manage L-DOPA's side effects.
• Human trials are required to confirm the effectiveness of dopamine-based treatments for Alzheimer's.